Publication at First Faculty of Medicine |
2017
Abstract
Renal cell carcinoma (RCC) has traditionally been considered an immunogenic malignancy. Despite this, the majority of existing immunotherapeutic strategies have brought only little benefit to patients with a generalized tumour.
In some clinical settings, however, a novel generation of immunotherapeutic drugs, particularly those from the group of checkpoint inhibitors, has shown superiority over standard targeted therapy, while having relatively low toxicity.